empagliflozin
eli lilly,boehringer ingelheim
['empag', 'empagliflozin', 'empa-kidney']
empa-kidney: among a wide range of patients w/ ckd who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cv causes (vs. placebo) ca. 2022 from #kidneywk #aha22 #nephpearls 
Chicago Sports Fan... Nephrologist by day. My tweets are not medical advice. The views expressed here are my own and not those of my employer.